On Invalid Date, Adagene (NASDAQ: ADAG) reported Q4 2022 earnings per share (EPS) of N/A, up N/A year over year. Total Adagene earnings for the quarter were N/A. In the same quarter last year, Adagene's earnings per share (EPS) was N/A.
On Invalid Date, Adagene (NASDAQ: ADAG) reported Q4 2022 revenue of N/A up N/A year over year. In the same quarter last year, Adagene's revenue was N/A.
What was ADAG's revenue growth in the past year?
As of Q2 2023, Adagene's revenue has grown -8.67% year over year. This is 77.89 percentage points lower than the US Biotechnology industry revenue growth rate of 69.21%. Adagene's revenue in the past year totalled $9.29 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.